Alzamend Neuro, Inc.
Clinical trials sponsored by Alzamend Neuro, Inc., explained in plain language.
-
Could a custom vaccine slow Alzheimer's? new trial begins
Disease control OngoingThis early-phase trial tests a personalized vaccine (ALZN002) made from a patient's own immune cells, designed to train the body to attack amyloid plaques in the brain. Thirty people with mild-to-moderate Alzheimer's will receive either the vaccine or a placebo. The main goal is …
Phase: PHASE1, PHASE2 • Sponsor: Alzamend Neuro, Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:08 UTC
-
New lithium formula could mean fewer side effects for brain disorders
Knowledge-focused OngoingThis early-stage study tests a new crystallized form of lithium (AL001) against standard lithium carbonate in 6 healthy adults. Participants take each drug for 14 days and undergo MRIs and blood draws to compare how much lithium reaches the brain. The goal is to see if AL001 is s…
Phase: PHASE1 • Sponsor: Alzamend Neuro, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC